Development of novel therapeutic agents targeted at pathogenetic factors such as neutrophil elastase inhibitors, bacterial biofilm dispersers, statins, chemokine receptor 2 (CXCR2) antagonists, new anti-pseudomonal compound based on the antimicrobial peptide protegrin, are welcome developments, given the complexities and drawbacks to the current treatment of bronchiectasis [21,40]. This evidence concerns the gene CXCR2 and bronchiectasis.